Identification of a Fusion/Entry Receptor for Human Herpesvirus-8


This invention relates to stable, nonhuman cell lines and transgenic mammals having cells that coexpress human xCT as valuable tools for the continuing research of Kaposi’s Sarcoma Herpes Virus (KSHV) infection and the development of more effective anti-KSHV therapeutics. Kaposi’s sarcoma (KS) is the most common malignancy in AIDS patients and manifests as highly proliferative vascular lesions that appear on body extremities. KSHV is invariably present in all known clinical forms of KS and sero-conversion to KSHV antigens is considered a risk factor for development of the lesions. KSHV is believed to enter target cells by direct fusion of virion membrane with the target cell plasma membrane. The susceptibility of KSHV infection depends on the cell surface expression of the human xCT molecule. xCT plays a role in the membrane fusion step of KSHV infection. The identification of xCT as a receptor for KSHV may pave the way for deciphering the mechanism of KSHV pathogenesis.

Potential Commercial Applications: Competitive Advantages:
s discovery has led to various potential commercial applications for this invention including the following:
  •   Cell lines expressing recombinant xCT for analysis of KSHV entry/infection
  •   Construction of xCT transgenic small animals for testing of KSHV inhibitors
  •   Use of peptides or fragments derived from extracellular regions of xCT as KSHV inhibitors
  •   Use of specific antibodies (including human versions) against xCT as KSHV inhibitors
  •   Use of small molecules targeted to xCT as KSHV inhibitors
 


Inventors:

Edward Berger (NIAID)  ➽ more inventions...

Johnan Kaleeba (NIAID)  ➽ more inventions...


Intellectual Property:
US Application No. PCT/US2006/018864
PCT Application No. 11/920,376

Licensing Contact:
Admin. Licensing Specialist (ALS),
Email:
Phone:

OTT Reference No: E-051-2005-0
Updated: Nov 1, 2005